Skip to main content

LATUDA (Servier Laboratories Australia Pty Ltd)

Product name
LATUDA
Date registered
Evaluation commenced
Decision date
Approval time
231 working days (255)
Active ingredients
lurasidone hydrochloride
Registration type
EOI
Indication
LATUDA is now also indicated for the treatment of schizophrenia in adolescents (aged 13 to 17 years).

Help us improve the Therapeutic Goods Administration site